Testing effectiveness (Phase 2)Looking for participantsNCT06830629What this trial is testingMZE829 in Adults With APOL1 Kidney DiseaseWho this might be right forProteinuric Kidney Disease Maze Therapeutics 56
Testing effectiveness (Phase 2)Looking for participantsNCT06824987What this trial is testingDose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney DiseaseWho this might be right forAPOL1-Mediated Kidney Disease AstraZeneca 96
Testing effectiveness (Phase 2)Study completedNCT04340362What this trial is testingPhase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental GlomerulosclerosisWho this might be right forGlomerulosclerosis, Focal Segmental Vertex Pharmaceuticals Incorporated 16
Early research (Phase 1)Study completedNCT05324410What this trial is testingDose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy ParticipantsWho this might be right forAPOL1-mediated Kidney Disease Vertex Pharmaceuticals Incorporated 88
Not applicableLooking for participantsNCT06839833What this trial is testingAPOL1 Genotyping CTA Clinical Performance StudyWho this might be right forAPOL1-mediated Kidney Disease Almac Diagnostic Services LLC 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT06794996What this trial is testingInaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesWho this might be right forProteinuric Kidney Disease Vertex Pharmaceuticals Incorporated 45
Large-scale testing (Phase 3)Looking for participantsNCT05312879What this trial is testingPhase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney DiseaseWho this might be right forProteinuric Kidney Disease Vertex Pharmaceuticals Incorporated 466